Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454046 | 0.92 | F10 (0.51) | F10TSHRALDH1A1HPGDLMNA | |
| SCHEMBL4447292 | 0.87 | F10 (0.47) | F10TSHRALDH1A1HPGDLMNA | |
| SCHEMBL4449727 | 0.82 | F10 (0.51) | F10TSHRALDH1A1HPGDLMNA | |
| SCHEMBL4456773 | 0.82 | F10 (0.50) | F10 | |
| SCHEMBL4448125 | 0.82 | F10 (0.54) | F10 | |
| SCHEMBL4447306 | 0.81 | F10 (0.55) | F10LMNASMN1; SMN2HTTMAPT | |
| SCHEMBL5541908 | 0.81 | F10 (0.49) | F10TSHRALDH1A1HPGDLMNA | |
| SCHEMBL4452304 | 0.77 | F10 (0.46) | F10TSHRALDH1A1HPGDLMNA | |
| SCHEMBL4444452 | 0.77 | F10 (0.46) | F10TSHRALDH1A1HPGDLMNA | |
| SCHEMBL4444453 | 0.77 | F10 (0.46) | F10TSHRALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557102-B2 | Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor Xa inhibitors for the treatment of thromboses | MERCK PATENT GMBH (DE) | 2009-07-07 | — | — | US | disclosed |
| US-20060183742-A1 | Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor xa inhibitors for the treatment of thromboses | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183742-A1 | Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor xa inhibitors for the treatment of thromboses | F2, SERPINC1, F12 | F10 7/4885TSHR 960/4885ALDH1A1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.